Biotechnology - Lemtrada, Pharmaceutical


Current filters:


Popular Filters

New entrants to multiple sclerosis market will drive 10% pa growth through 2018


The market for disease-modifying multiple sclerosis (MS) therapies will expand at an annual rate of 10%…

AbbVieAubagioBayerBiogen IdecBiotechnologydaclizumabGlobalLemtradaMarkets & MarketingNeurologicalocrelizumabPharmaceuticalRocheSanofiTecfidera

Genzyme says Lemtrada sBLA for MS accepted by FDA; reports on Aubagio


French drug major Sanofi (Euronext: SAN) US biotech subsidiary Genzyme says that the US Food and Drug…

AubagioBiotechnologyGenzymeLemtradaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

News briefs: Eli Lilly expands insulin facility; and Sanofi criticized over Lemtrada


US drug major Eli Lilly (NYSE: LLY) has announced a $140 million expansion to the company's Indianapolis…

BiotechnologyDiabetesEli LillyLemtradaNeurologicalPharmaceuticalPricingProductionSanofi

News briefs from Sanofi, Biogen/SOBI and Novartis


French drug major Sanofi (Euronext: SAN) and subsidiary Genzyme have reported results from pivotal studies…

AgrippalBiogen IdecBiotechnologyFluadLemtradaNeurologicalNovartisPharmaceuticalRegulationResearchSanofiSwedish Orphan BiovitrumVaccines

FDA calls on Genzyme to re-file Lemtrada sBLA


French drug major Sanofi (Euronext: SAN) revealed yesterday that its US biotech subsidiary has received…

BayerBiotechnologyGenzymeLemtradaNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

European neurologists view Rxing of Biogen Idec's BG-12, Sanofi's Aubagio and Sanofi/Bayer's Lemtrada


More than 85% of surveyed neurologists in the European Union-5 (France, Germany, Italy, Spain and the…

AubagioBayerBG-12Biogen IdecBiotechnologyEuropeLemtradaMarkets & MarketingNeurologicalPharmaceuticalSanofi

Genzyme files multiple sclerosis drug Lemtrada with FDA and EMA


French drug major Sanofi (Euronext: SAN) subsidiary Genzyme revealed this morning that it has submitted…

BayerBiotechnologyEuropeGenzymeLemtradaNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

Biogen jumps on strong MS drug data: Sanofi’s Lemtrada significant improvement on Rebif


US biotech firm Biogen Idec (Nasdaq: BIIB) saw its shares jump 6% to $107.53 last Friday, after the company…

AlemtuzumabBiogen IdecBiotechnologydaclizumabdimethyl fumarateGenzymeLemtradaNeurologicalPharmaceuticalResearchSanofi

Back to top